Christian Poehlein
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 50
- PARP inhibition in cancer therapy 17
- Immunology top 2%
- Immunotherapy and Immune Responses 14
- Immune Cell Function and Interaction 8
- Surgery top 2%
- Bladder and Urothelial Cancer Treatments 7
-
- Prostate Cancer Treatment and Research 53
- Renal cell carcinoma treatment 6
- Cancer Research top 5%
-
- Radiopharmaceutical Chemistry and Applications 26
- Co-authors
- Daniel P. PetrylakHoward GurneyJae‐Lyun LeeToni K. ChoueiriJoaquim BellmuntDavid I. QuinnRonald de WitYves Fradet
- Cited by
- OncologyImmunologySurgery
- Journals
- Journal of Clinical Oncology (35 papers)Annals of Oncology (9 papers)The Journal of Immunology (2 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Christian Poehlein
74 papers receiving 3.8k citations
Hit Papers
Peers
Comparison fields: 5 of 91
- Oncology 2.7k
- Immunology 1.1k
- Surgery 1.6k
- Pulmonary and Respiratory Medicine 1.2k
- Cancer Research 351
Countries citing papers authored by Christian Poehlein
This map shows the geographic impact of Christian Poehlein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian Poehlein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian Poehlein more than expected).
Fields of papers citing papers by Christian Poehlein
This network shows the impact of papers produced by Christian Poehlein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian Poehlein. The network helps show where Christian Poehlein may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Christian Poehlein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 3 | |
| 5 | Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trialbreakdown → | 2023 | 132 |
| 6 | 2023 | 6 | |
| 7 | 2023 | 24 | |
| 8 | 2022 | 6 | |
| 9 | 2021 | 2 | |
| 10 | 2020 | 3 | |
| 11 | 2019 | 41 | |
| 12 | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinomabreakdown → | 2017 | 2374 |
| 13 | 2017 | 2 | |
| 14 | 2012 | 203 | |
| 15 | 2009 | 27 | |
| 16 | 2008 | 5 | |
| 17 | 2007 | 14 | |
| 18 | 2003 | 56 | |
| 19 | 1997 | 25 | |
| 20 | 1997 | 36 |
About Christian Poehlein
Christian Poehlein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 79 papers that have together received 3.8k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (53 papers), Cancer Immunotherapy and Biomarkers (50 papers), Radiopharmaceutical Chemistry and Applications (26 papers), PARP inhibition in cancer therapy (17 papers), Immunotherapy and Immune Responses (14 papers), Immune Cell Function and Interaction (8 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Renal cell carcinoma treatment (6 papers). The work is most often cited by research in Oncology (2.7k citations), Immunology (1.1k citations) and Surgery (1.6k citations). Christian Poehlein has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Daniel P. Petrylak, Howard Gurney, Jae‐Lyun Lee, Toni K. Choueiri, Joaquim Bellmunt, David I. Quinn, Ronald de Wit, Yves Fradet, Dean F. Bajorin and Nicholas J. Vogelzang. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Journal of Immunology, European Urology Oncology and Journal of Translational Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.